MaxCyte, Inc. Grant of Options (6906L)
21 July 2017 - 3:02AM
UK Regulatory
TIDMMXCT TIDMMXCR
RNS Number : 6906L
MaxCyte, Inc.
20 July 2017
MaxCyte, Inc.
("MaxCyte" or the "Company")
Grant of Options
Maryland, USA - 20 July 2017: MaxCyte (LSE: MXCT, MXCR), a
US-based global company dedicated to driving the acceleration of
the discovery, development, manufacturing and commercialisation of
next-generation, cell-based medicines, announces that it has
granted, effective July 14, 2017, a total of 686,400 options of
common stock in the Company ("Common Stock") to PDMRs who are
directors or officers of the Company ("Option Grants"). Details of
the Option Grants are given below:
Option Grants
to PDMRs
-------------------- --------
Doerfler, Doug 296,000
-------------------- --------
Holtz, Ron 134,800
-------------------- --------
Madhusudan, Peshwa 136,100
-------------------- --------
Thompson, J. Stark 23,900
-------------------- --------
Mandell, Art 23,900
-------------------- --------
Erck, Stan 23,900
-------------------- --------
Brooke, Will 23,900
-------------------- --------
Johnston, John 23,900
-------------------- --------
Total 686,400
-------------------- --------
Options Grants to PDMRs vest ratably on a monthly basis over 48
months, have an exercise period of 10 years from date of grant, at
which time they will expire, and have an exercise price equal to
the closing price of MaxCyte's stock on July 14, 2017, of 242.50
pence.
About MaxCyte
MaxCyte (LSE: MXCT, MXCR) is a US-based global company dedicated
to driving the acceleration of the discovery, development,
manufacturing and commercialization of next-generation, cell-based
medicines. The Company provides its patented, high-performance cell
engineering platform to biopharmaceutical partners engaged in drug
discovery and development, biomanufacturing, and cell therapy,
including gene editing and immuno-oncology. With its robust
delivery platform, MaxCyte's team of scientific experts helps its
partners to unlock their product potential and solve problems. This
platform allows for the engineering of nearly all cell types,
including human primary cells, with any molecule, at any scale. It
also provides a high degree of consistency and minimal cell
disturbance, thereby facilitating rapid, large-scale, clinical and
commercial grade cell engineering in a non-viral system and with
low-toxicity concerns. The Company's cell-engineering platform is
FDA-accredited, providing MaxCyte's customers and partners with an
established regulatory path to commercialize cell-based medicines.
MaxCyte is also developing CARMA, its proprietary, breakthrough
platform in immuno-oncology, to rapidly manufacture CAR therapies
for a broad range of cancer indications, including solid tumors
where existing CAR-T approaches face
significant challenges. For more information, visit http://www.maxcyte.com/
###
MaxCyte Inc.
Doug Doerfler, Chief Executive
Officer
Ron Holtz, Chief Financial
Officer +1 301 944 1660
Nominated Adviser and Broker
Panmure Gordon
Freddy Crossley (Corporate
Finance)
Duncan Monteith
Ryan McCarthy
Tom Salvesen (Corporate Broking) +44 (0) 20 7886 2500
Financial PR Adviser
Consilium Strategic Communications
Mary-Jane Elliott +44 (0)203 709 5700
Chris Welsh maxcyte@consilium-comms.com
Lindsey Neville
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ---------------------------------------------------------------
a) Names Doerfler, Doug
Holtz, Ron
Madhusudan, Peshwa
Thompson, J. Stark
Mandell, Art
Erck, Stan
Brooke, Will
Johnston, John
--- ----------------------- --------------------------------------
2 Reason for the notification
--- ---------------------------------------------------------------
a) Position/status Doerfler, Doug - CEO and Director
Holtz, Ron - CFO and Director
Madhusudan, Peshwa - CSO
Thompson, J. Stark - Non-executive
Chairman
Mandell, Art - Non-executive
Director
Erck, Stan - Non-executive Director
Brooke, Will - Non-executive
Director
Johnston, John - Non-executive
Director
--- ----------------------- --------------------------------------
b) Initial notification Initial Notification
/Amendment
--- ----------------------- --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ---------------------------------------------------------------
a) Name MaxCyte, Inc.
--- ----------------------- --------------------------------------
b) LEI 54930053YHXULRFCU991
--- ----------------------- --------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- ---------------------------------------------------------------
a) Description Grant of Options over Shares
of the financial of Common Stock
instrument,
type of instrument
--- ----------------------- --------------------------------------
b) Identification US57777K1060
code
--- ----------------------- --------------------------------------
c) Nature of the
transactions Grant of Options to PDMRs
--- ----------------------- --------------------------------------
d) Price(s) and Doerfler, Doug - 296,000 at an
volume(s) exercise price of 242.50 pence
Holtz, Ron - 134,800 at an exercise
price of 242.50 pence
Madhusudan, Peshwa - 136,100
at an exercise price of 242.50
pence
Thompson, J. Stark - 23,900 at
an exercise price of 242.50 pence
Mandell, Art - 23,900 at an exercise
price of 242.50 pence
Erck, Stan - 23,900 at an exercise
price of 242.50 pence
Brooke, Will - 23,900 at an exercise
price of 242.50 pence
Johnston, John - 23,900 at an
exercise price of 242.50 pence
--- ----------------------- --------------------------------------
d) Aggregated information n/a
- Aggregated
volume
- Price
--- ----------------------- --------------------------------------
e) Date of the 14 July 2017
transactions
--- ----------------------- --------------------------------------
f) Place of the Outside a trading venue
transaction
--- ----------------------- --------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHEAXXEAEEXEFF
(END) Dow Jones Newswires
July 20, 2017 13:02 ET (17:02 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024